Back to search results

Comparing ABP 692 to Ocrevus® for Relapsing-remitting Multiple Sclerosis

This study is comparing a drug called ABP 692 to Ocrevus® (ocrelizumab), which is already approved for treating relapsing-remitting multiple sclerosis (RRMS). Researchers want to see if ABP 692 acts similarly in the body to Ocrevus®. You might be able to join if you are 18 to 99 years old, have been diagnosed with RRMS based on specific criteria, and have had recent MS activity but no relapse in the last 28 days. The study will measure how much of the drugs are in your body over time to determine if they are similar. The current status of this study is unclear, and it plans to enroll 152 participants.

Study design
This interventional study aims to enroll 152 participants. It is comparing three different drug interventions: Ocrelizumab (US), Ocrelizumab (EU), and ABP 692, all given as IV infusions.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures drug levels up to 15 days after the first infusion and up to 16 weeks after the initial dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06700343

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Active, Not Recruiting
PHASE3Ages 18–99InterventionalTreatment
Amgen
~152 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:Ocrelizumab (US)Ocrelizumab (EU)ABP 692

At a glance

Recruiting sites
0 of 109 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)
Measured over Day 1 to Day 15
+1 more outcome measured

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)

Explore related trials

Relapsing-Remitting Multiple Sclerosis

NCT06700343

Where you'd take part

This study runs at 109 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Aarhus Universitetshospital, Skejby

    Aarhus N, Central Jutland, Denmarkno site contact published

  • Academic Specialist Center

    Stockholm, Swedenno site contact published

  • Advanced Neurosciences Research, Llc

    Fort Collins, Coloradono site contact published

  • Algemeen Ziekenhuis Delta

    Roeselare, West-Vlaanderen, Belgiumno site contact published

  • Aqualane Clinical Research

    Naples, Floridano site contact published

  • Arencia Exploratory Medicine

    Kyiv, Ukraineno site contact published

  • ARENSIA Clinics

    Bucharest, Romaniano site contact published

  • ARENSIA Exploratory Medicine at County Hospital Cluj-Napoca

    Cluj-Napoca, Romaniano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • MD · STUDY_DIRECTOR · Amgen

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)Day 1 to Day 15
  • AUC From Time 0 Extrapolated toInfinity (AUC0-inf) of the Entire Initial Dose of IPDay 1 to Week 16